Merck & Company
West Coast Innovation Hub
499 Illinois St. Suite 100
About Merck & Company
Meet representatives from Merck and connect with your Life Science peers at our 2018 Biotech Bay and Genetown Fall Talent Connect. Learn more about Merck here.
Merck and Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories directly and through its joint ventures. Our mission is to provide society with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.
With approximately 60,000 employees, Merck conducts research at ten major research centers in the United States, Europe, and Japan, manufactures products in 30 facilities, and sells products in approximately 150 countries.
At Merck, our strategy for growth is based on breakthrough research - both internal and external through partnerships - and demonstrating the value of our medicines to patients, payers, and providers. Worldwide sales in 2004 were $22.9 billion. Merck continues to invest heavily in research and development, with R&D spending in 2005 estimated to be approximately $4 billion.
Merck's product line includes a broad portfolio of highly innovative prescription products in important therapeutic areas. Human health products include medicines to treat high blood pressure, congestive heart failure, elevated cholesterol levels, osteoporosis, benign prostatic hypertrophy, arthritis, pain, migraine, glaucoma, gastrointestinal ulcers, infectious diseases (antibiotic, anti-fungal, and antiviral agents), and vaccines to prevent childhood diseases and hepatitis A and B.
At Merck, we are strongly committed to partnership success. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral part of our long-term business and research strategy. More than one-third of our sales are from alliance products and patents, including some of our biggest growth drivers.
Our vision is to create a "virtual lab" - the pursuit of the best scientific programs from both internal research and external collaborations. This approach will accelerate the successful development and commercialization of breakthrough discoveries that can bring meaningful improvements to patients' lives.
Our focus is seeking alliances for new NCE's and biological entities as product candidates for development. We are open to basic research collaborations and early research technologies as well.
Merck welcomes partnerships touching virtually all human health therapeutic areas that address unmet needs for patients, as well as technologies that will enhance the productivity of our research laboratories. Therapeutic areas of particular interest include cancer, central nervous system disorders, diabetes, and obesity. Also of interest include the following: anti-infectives, anti-virals, cardiovascular diseases, gastrointestinal diseases, immunology, new vaccine technology, ophthalmics, osteoporosis, pain, respiratory, vaccines, and platform research technology.
To contact Merck about a licensing opportunity, please contact Chief Licensing Officer, Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889 USA; Fax: 908-735-1201. Please provide a brief, non-confidential overview of your discovery with sufficient data to allow a preliminary scientific review.
For further information, please visit our website at http://www.merck.com/licensing/
277 articles with Merck & Company
Merck Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO™ (doravirine) in the European Union for the Treatment of HIV-1 Infection
Merck today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO™
Report Illustrates How Merck Creates Sustainable Value for Business and Society
Accenture and Merck Collaborate with Amazon Web Services to Launch a Research Platform to Drive Innovation in Drug Discovery and Scientific Research
Cloud-based informatics research platform designed to help organizations in the life sciences industry improve productivity, efficiency and innovation in the early stages of drug development.
The Morgan Stanley Global Healthcare Conference ran from September 12 through 14, with numerous biopharma companies making presentations, updating their operations and pipeline activities. Here’s a look a few of the highlights.
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%)
Application Based on Overall Survival Data from Pivotal Phase 3 KEYNOTE-042 Trial
Data from Merck’s Leading Lung Cancer Research Program with KEYTRUDA® (pembrolizumab) to be Presented at IASLC 19th World Conference on Lung Cancer
Merck today announced that investigational data from the company’s leading lung cancer research program with KEYTRUDA, Merck’s anti-PD-1 therapy, will be presented at the IASLC 19th World Conference on Lung Cancer
Eisai and Merck Announce China National Medical Products Administration (NMPA) Approval of LENVIMA® (lenvatinib) for Treatment of Unresectable Hepatocellular Carcinoma (HCC)
First Approval for LENVIMA in China and First New Therapy for the First-line Treatment of Unresectable HCC Approved in China in a Decade
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the Treatment of Merkel Cell Carcinoma, a Rare Form of Skin Cancer
Application Based on Data from Phase 2 KEYNOTE-017 Trial
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
8/31/2018The U.S. Food and Drug Administration has had a busy August. In addition to the number of draft guidance documents the agency issued during the month, the FDA has also been busy approving a number of new treatments for a variety of diseases.
AT&T, Softbox and Merck Test Connected Payloads and Drone Flights to Deliver Medical Supplies in Puerto Rico
AT&T* is taking part in a proof of concept with Softbox to test connected medical payloads carried by drones.
Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA® (lenvatinib) as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma
First new, first-line treatment option for advanced or unresectable HCC approved in Europe in a decade
GlucoMe and Merck KGaA, Darmstadt, Germany to Collaborate on Digital Diabetes Management Project in Vietnam
GlucoMe has entered into a pilot collaboration agreement with Merck KGaA, Darmstadt, Germany to evaluate GlucoMe's digital diabetes platform across several hospitals in Vietnam.
Vantage Pharma published a report that reviewed the biopharma and medical technology trends for the year-to-date. Broadly speaking, for biotech companies, venture capital investment is up and mergers and acquisitions is down, while for the medical device company it’s the reverse.
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma
Approval was based on REFLECT, the first-ever positive Phase 3 trial against an active comparator in previously untreated patients with unresectable HCC
Synthorx, Inc. today announced the appointment of Joseph Leveque, M.D., as chief medical officer.
Merck Foundation Supports New Programs to Improve Care for Alzheimer's Patients And Caregivers in the United States
These programs are part of the Foundation's $5 million effort to reduce disparities in health care for underserved communities affected by Alzheimer's
Geisinger and Merck Unveil New Applications Developed to Help Improve Patient Communication and Care Delivery
Collaboration Yields Family Caregiver Application and MedTrue™ Workflow Solutions
Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
Merck’s Head of Human Resources Mirian M. Graddick-Weir to Retire; Steven C. Mizell Will Assume Role on Oct. 1
Merck announced the retirement effective November 30, 2018 of its chief human resources officer Mirian M. Graddick-Weir, following 12 years of service with the company.